menu
    • menu
    [{"orgOrder":0,"company":"Erkim","sponsor":"MEDICE Health Family","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"TURKEY","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Erkim \/ MEDICE Health Family","highestDevelopmentStatusID":"15","companyTruncated":"Erkim \/ MEDICE Health Family"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Roxadustat","moa":"HIF-PHI","graph1":"Nephrology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0.16,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0.16,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"FibroGen \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ AstraZeneca"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Ardelyx","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fosun Pharmaceutical \/ Ardelyx","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Pharmaceutical \/ Ardelyx"},{"orgOrder":0,"company":"Mundipharma","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mundipharma \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ GSK"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Tai Tien Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mitsubishi Tanabe Pharma \/ Tai Tien Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Tai Tien Pharmaceutical"},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Napp Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Napp Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Napp Pharmaceuticals \/ GSK"},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Napp Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Napp Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Napp Pharmaceuticals \/ GSK"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/chloride reabsorption","graph1":"Nephrology","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tiopronin","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cycle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Leerink Partners"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Akebia Therapeutics

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Akebia Therapeutics

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vadadustat

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Leerink Partners

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

                            Details : The proceeds from the offering will be used for R&D and commercialization of Vafseo (vadadustat) which is approved for the treatment of anemia due to chronic kidney disease in adults.

                            Product Name : Vafseo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 19, 2025

                            Lead Product(s) : Vadadustat

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Leerink Partners

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Akebia Therapeutics

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Akebia Therapeutics

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vadadustat

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Leerink Partners

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Akebia Therapeutics Announces Proposed Public Offering of Common Stock

                            Details : The proceeds from the offering will be used for R&D and commercialization of Vafseo (vadadustat) which is approved for the treatment of anemia due to chronic kidney disease in adults.

                            Product Name : Vafseo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 19, 2025

                            Lead Product(s) : Vadadustat

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Leerink Partners

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cycle Pharmaceuticals

                            United Kingdom arrow
                            DCAT Week
                            Not Confirmed

                            Cycle Pharmaceuticals

                            United Kingdom arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiopronin

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            US Launch of VENXXIVA for Cystinuria Treatment

                            Details : Venxxiva is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation with severe homozygous cystinuria.

                            Product Name : Venxxiva

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 18, 2025

                            Lead Product(s) : Tiopronin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            scPharmaceuticals

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            scPharmaceuticals

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            scPharmaceuticals Expands FUROSCIX® Indication for CKD-Related Edema

                            Details : scPharmaceuticals is developing FUROSCIX, a proprietary, subcutaneously delivered furosemide solution, as an outpatient alternative for the treatment of edema in patients with chronic kidney disease.

                            Product Name : Furoscix

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 06, 2025

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Fosun Pharmaceutical

                            China arrow
                            DCAT Week
                            Not Confirmed

                            Fosun Pharmaceutical

                            China arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor Hydrochloride

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Ardelyx

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)

                            Details : Wan Ti Le (tenapanor HCl) is a sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for treatment of chronic kidney disease.

                            Product Name : Wan Ti Le

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 26, 2025

                            Lead Product(s) : Tenapanor Hydrochloride

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Ardelyx

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            FibroGen

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            FibroGen

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roxadustat

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : AstraZeneca

                            Deal Size : $160.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            FibroGen Sells FibroGen China to AstraZeneca for $160M

                            Details : Through the acquisition, AstraZeneca will integrate FibroGen China and gain full rights to Evrenzo (roxadustat) in China. It is currently being evaluated for the treatment of chronic kidney disease.

                            Product Name : Evrenzo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 20, 2025

                            Lead Product(s) : Roxadustat

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : AstraZeneca

                            Deal Size : $160.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Erkim

                            Turkey arrow
                            DCAT Week
                            Not Confirmed

                            Erkim

                            Turkey arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vadadustat

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : MEDICE Health Family

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Er-Kim Announces Distribution Agreement with MEDICE for Vafseo® in Europe

                            Details : Under the agreement, Er-Kim partner with the MEDICE to commercialize the Vafseo (vadadustat). It is being indicated for the treatment of of symptomatic anaemia associated with CKD in adults.

                            Product Name : Vafseo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 14, 2025

                            Lead Product(s) : Vadadustat

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : MEDICE Health Family

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Mitsubishi Tanabe Pharma

                            Japan arrow
                            DCAT Week
                            Not Confirmed

                            Mitsubishi Tanabe Pharma

                            Japan arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canagliflozin

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Tai Tien Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Canagliflozin (TA-7284) has Been Approved in Taiwan For Diabetic Nephropathy

                            Details : Tai Tien Pharmaceuticals has obtained the regulatory approval of CANAGLU® (CANAGLU)(INN: canagliflozin; Japan names: CANAGLU® Tablets 100mg) for a treatment agent for diabetic nephropathy in Taiwan FDA.

                            Product Name : Canaglu

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            February 26, 2021

                            Lead Product(s) : Canagliflozin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Tai Tien Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mundipharma

                            Germany arrow
                            DCAT Week
                            Not Confirmed

                            Mundipharma

                            Germany arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canagliflozin

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mundipharma Gets E.C Approval for Extended Invokana® (Canagliflozin) Indication to Cover Diabetic KD in Type ...

                            Details : The EC approval is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which achieved pre-specified efficacy criterion.

                            Product Name : Invokana

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            July 03, 2020

                            Lead Product(s) : Canagliflozin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Napp Pharmaceuticals

                            United Kingdom arrow
                            DCAT Week
                            Not Confirmed

                            Napp Pharmaceuticals

                            United Kingdom arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canagliflozin

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Napp Pharmaceuticals Announces European Commission Approval of Invokana® (canagliflozin) Label Update to Refl...

                            Details : The European Commission approval is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which was stopped early based on the achievement of a pre-specified efficacy c...

                            Product Name : Invokana

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            July 02, 2020

                            Lead Product(s) : Canagliflozin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth